Form 4: Vericel Corp Director Heidi Hagen Reports Stock Transactions

Director Heidi Hagen reports acquisition of Vericel Corp common stock through vesting of Restricted Stock Units (RSUs) and grant of stock options.

Summary

• Heidi Hagen, a director of Vericel Corp, reported transactions involving the company's stock on May 1, 2024.
• These transactions include the acquisition of 3,200 shares of common stock through the vesting of Restricted Stock Units (RSUs) granted on May 3, 2023.
• Hagen also acquired 8,000 stock options with an exercise price of $47.08, vesting monthly over one year from May 1, 2024, and expiring on May 1, 2034.
• Additionally, 3,200 RSUs were granted, vesting on the earlier of May 1, 2025, or the date of the first Annual Meeting of Stockholders following May 1, 2024.
• Following these transactions, Hagen directly owns 18,650 shares of Vericel Corp common stock, 8,000 stock options, and 3,200 RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating stock transactions by a director, which can be interpreted as a sign of confidence, but it doesn't provide strong positive or negative signals.

Positives

• The acquisition of shares and options by a director could be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly increasing the number of outstanding shares as RSUs vest and options are exercised.

Key Dates